Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Affordable Care Act
    • Consumer-Driven Health Care
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Drug Prices & Regulations
    • Health Economics & Costs
    • Health Insurance
    • Health Reform
    • Medical Tourism
    • Medicare
    • Single-Payer/Medicare-for-All
    • Telemedicine
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Pfizer’s View of its Own Vaccine

Posted on June 30, 2022June 30, 2022 by John C. Goodman

Turns out, it is very positive. But in a review of Pfizer CEO Albert Bourla’s book, Moonshot, Robert Kaplan asks:

How transparent has Pfizer been? In the book’s more than 200 pages, one topic is not explored in any real depth—side effects. Although the vaccine is generally regarded as safe, side effects do appear to be more common—and perhaps more severe—than for other widely used vaccines. In the 2020 clinical trial that provided the basis for FDA emergency-use authorization, more than 83% of 18- to 55-year-old participants (in comparison with 14% of those injected with a placebo) reported arm pain after their first shot, and approximately a third had a fever in reaction to their second (in contrast to less than 1% for a placebo).

And there is more:

…  science is a process that works best when research findings are peer-reviewed and when calculations are verified by independent scientists with no vested interest in a commercial product. Pfizer skipped this step. Instead, it used internally controlled trials and first made the results public through highly curated press releases that showed its evidence in the best light.

Even now, Pfizer has not released data that would allow independent scientists to verify its analyses.

Join the conversation. Cancel reply

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 11 other subscribers

Popular Topics

©2023 The Goodman Institute Health Blog | Website by Lexicom